(ACLX) Arcellx - Ratings and Ratios
Anitocabtagene, ACLX-001, ACLX-002, ACLX-003, Arc-SparX
ACLX EPS (Earnings per Share)
ACLX Revenue
Description: ACLX Arcellx
Arcellx Inc (NASDAQ:ACLX) is a biotechnology company focused on developing innovative immunotherapies for cancer and other incurable diseases. The companys lead product candidate, anitocabtagene autoleucel, is in Phase 2 clinical trials for relapsed or refractory multiple myeloma (rrMM), a potentially lucrative market given the high unmet need for effective treatments.
From a clinical development perspective, Arcellx has a diverse pipeline with multiple programs targeting various hematological malignancies, including rrMM, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). The companys ACLX-001 and ACLX-002 programs are in Phase 1 clinical trials, while ACLX-003 is in preclinical development. This diversified pipeline reduces reliance on a single program and increases potential revenue streams.
Key performance indicators (KPIs) to monitor Arcellxs progress include: (1) patient enrollment and retention rates in ongoing clinical trials, (2) interim and final data readouts from these trials, (3) progress in preclinical development and IND filings for new programs, and (4) strategic partnerships and collaborations, such as the existing alliance with Kite Pharma, Inc. A successful partnership can provide significant funding and expertise, accelerating the development and commercialization of Arcellxs product candidates.
From a financial perspective, Arcellxs market capitalization is approximately $3.72 billion, indicating a moderate level of investor confidence. The absence of a price-to-earnings (P/E) ratio is expected given the companys focus on R&D and lack of commercial-stage products. Return on Equity (RoE) is -35.27%, reflecting significant investment in R&D. Cash burn rate, operating expenses, and funding milestones are essential KPIs to track the companys financial sustainability.
To further evaluate Arcellxs potential, its essential to analyze the competitive landscape, including the market share and growth prospects of its product candidates, as well as the companys intellectual property position and manufacturing capabilities. A strong competitive position and robust IP protection can significantly enhance the companys value proposition.
ACLX Stock Overview
| Market Cap in USD | 3,950m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-02-04 |
ACLX Stock Ratings
| Growth Rating | 42.4% |
| Fundamental | 33.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -17.3% |
| Analyst Rating | 4.67 of 5 |
ACLX Dividends
Currently no dividends paidACLX Growth Ratios
| Growth Correlation 3m | 80.6% |
| Growth Correlation 12m | -50.8% |
| Growth Correlation 5y | 91.9% |
| CAGR 5y | 61.60% |
| CAGR/Max DD 3y | 1.22 |
| CAGR/Mean DD 3y | 3.38 |
| Sharpe Ratio 12m | 0.57 |
| Alpha | 0.10 |
| Beta | 0.833 |
| Volatility | 48.68% |
| Current Volume | 506.7k |
| Average Volume 20d | 398.9k |
| Stop Loss | 73.1 (-4.3%) |
| Signal | -0.77 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-188.0m TTM) > 0 and > 6% of Revenue (6% = 3.42m TTM) |
| FCFTA -0.16 (>2.0%) and ΔFCFTA -41.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 600.3% (prev 305.3%; Δ 295.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.19 (>3.0%) and CFO -118.2m > Net Income -188.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.81 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.2m) change vs 12m ago 5.05% (target <= -2.0% for YES) |
| Gross Margin 94.82% (prev 97.77%; Δ -2.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 8.42% (prev 19.71%; Δ -11.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1456 (EBITDA TTM -187.4m / Interest Expense TTM 133.0k) >= 6 (WARN >= 3) |
Altman Z'' -4.35
| (A) 0.55 = (Total Current Assets 463.9m - Total Current Liabilities 121.8m) / Total Assets 619.1m |
| (B) -0.99 = Retained Earnings (Balance) -611.9m / Total Assets 619.1m |
| (C) -0.29 = EBIT TTM -193.7m / Avg Total Assets 676.7m |
| (D) -2.70 = Book Value of Equity -611.4m / Total Liabilities 226.9m |
| Total Rating: -4.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.17
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -2.68% = -1.34 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.29 = 2.46 |
| 5. Debt/Ebitda -0.60 = -2.50 |
| 6. ROIC - WACC (= -53.18)% = -12.50 |
| 7. RoE -43.04% = -2.50 |
| 8. Rev. Trend 47.72% = 3.58 |
| 9. EPS Trend 9.46% = 0.47 |
What is the price of ACLX shares?
Over the past week, the price has changed by +5.10%, over one month by +6.40%, over three months by +21.53% and over the past year by -2.01%.
Is Arcellx a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACLX is around 90.48 USD . This means that ACLX is currently undervalued and has a potential upside of +18.4% (Margin of Safety).
Is ACLX a buy, sell or hold?
- Strong Buy: 12
- Buy: 6
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 113.1 | 48% |
| Analysts Target Price | 113.1 | 48% |
| ValueRay Target Price | 101.2 | 32.4% |
Last update: 2025-09-05 04:30
ACLX Fundamental Data Overview
CCE Cash And Equivalents = 453.1m USD (Cash And Short Term Investments, last quarter)
P/S = 69.32
P/B = 10.0787
Beta = 0.281
Revenue TTM = 57.0m USD
EBIT TTM = -193.7m USD
EBITDA TTM = -187.4m USD
Long Term Debt = 105.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 7.42m USD (from shortTermDebt, last quarter)
Debt = 112.4m USD (Calculated: Short Term 7.42m + Long Term 105.0m)
Net Debt = -9.82m USD (from netDebt column, last quarter)
Enterprise Value = 3.61b USD (3.95b + Debt 112.4m - CCE 453.1m)
Interest Coverage Ratio = -1456 (Ebit TTM -193.7m / Interest Expense TTM 133.0k)
FCF Yield = -2.68% (FCF TTM -96.9m / Enterprise Value 3.61b)
FCF Margin = -170.1% (FCF TTM -96.9m / Revenue TTM 57.0m)
Net Margin = -329.9% (Net Income TTM -188.0m / Revenue TTM 57.0m)
Gross Margin = 94.82% ((Revenue TTM 57.0m - Cost of Revenue TTM 2.95m) / Revenue TTM)
Tobins Q-Ratio = -5.90 (set to none) (Enterprise Value 3.61b / Book Value Of Equity -611.4m)
Interest Expense / Debt = 0.12% (Interest Expense 133.0k / Debt 112.4m)
Taxrate = 21.0% (US default)
NOPAT = -193.7m (EBIT -193.7m, no tax applied on loss)
Current Ratio = 3.81 (Total Current Assets 463.9m / Total Current Liabilities 121.8m)
Debt / Equity = 0.29 (Debt 112.4m / last Quarter total Stockholder Equity 392.2m)
Debt / EBITDA = -0.60 (Net Debt -9.82m / EBITDA -187.4m)
Debt / FCF = -1.16 (Debt 112.4m / FCF TTM -96.9m)
Total Stockholder Equity = 436.7m (last 4 quarters mean)
RoA = -30.37% (Net Income -188.0m, Total Assets 619.1m )
RoE = -43.04% (Net Income TTM -188.0m / Total Stockholder Equity 436.7m)
RoCE = -35.75% (Ebit -193.7m / (Equity 436.7m + L.T.Debt 105.0m))
RoIC = -44.35% (NOPAT -193.7m / Invested Capital 436.7m)
WACC = 8.83% (E(3.95b)/V(4.06b) * Re(9.08%)) + (D(112.4m)/V(4.06b) * Rd(0.12%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 2.29%
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -96.9m)
EPS Correlation: 9.46 | EPS CAGR: 189.6% | SUE: 0.17 | # QB: 0
Revenue Correlation: 47.72 | Revenue CAGR: 91.84% | SUE: N/A | # QB: None
Additional Sources for ACLX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle